People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Tentarix Biotherapeutics, LP | — | Biotechnology | Series B | $43.0M | $358.6M | 2023 |
Allyson F. Tighe at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Allyson F. Tighe on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jerel Davis | 1 | 13 |
| Srinivas Akkaraju | 1 | 10 |
| PAUL Grayson | 1 | 5 |
| Cory Freedland | 1 | 3 |
| Donald J. Santel | 1 | 2 |
| Alyssa Lochbaum | 1 | 1 |
| Paul Kang | 1 | 1 |
| Thomas F. Bumol | 1 | 1 |
| Margaret F. Karow | 1 | 1 |
| Stephen F. Demarest | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.